1. Home
  2. TRP vs ARGX Comparison

TRP vs ARGX Comparison

Compare TRP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TC Energy Corporation

TRP

TC Energy Corporation

HOLD

Current Price

$53.73

Market Cap

56.3B

Sector

N/A

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$788.10

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRP
ARGX
Founded
1951
2008
Country
Canada
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.3B
52.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TRP
ARGX
Price
$53.73
$788.10
Analyst Decision
Buy
Strong Buy
Analyst Count
1
19
Target Price
$84.00
$976.28
AVG Volume (30 Days)
2.0M
315.7K
Earning Date
02-13-2026
02-26-2026
Dividend Yield
4.58%
N/A
EPS Growth
N/A
N/A
EPS
2.34
23.27
Revenue
$10,516,264,743.00
$3,683,281,000.00
Revenue This Year
$11.69
$91.44
Revenue Next Year
$6.23
$36.90
P/E Ratio
$22.85
$32.42
Revenue Growth
24.53
92.98
52 Week Low
$43.51
$510.06
52 Week High
$56.34
$934.62

Technical Indicators

Market Signals
Indicator
TRP
ARGX
Relative Strength Index (RSI) 44.73 29.92
Support Level $52.71 $787.02
Resistance Level $56.08 $830.30
Average True Range (ATR) 1.03 19.22
MACD -0.29 -5.67
Stochastic Oscillator 28.10 1.42

Price Performance

Historical Comparison
TRP
ARGX

About TRP TC Energy Corporation

TC Energy operates natural gas transmission assets across North America. Segments are determined by country of operation, but both Canadian and US operations are interconnected. Mexican operations are disconnected from the US and only have one customer, the state utility CFE. They also operate power generation assets, with the largest being the Bruce Power nuclear plant.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: